MREO - Mereo BioPharma Group plc

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• HSBC, CLVS and HUT among pre market gainers
• AstraZeneca considering bid for Mereo BioPharma – Report (update)
• Mereo BioPharma falls as price target lowered to $5 at Needham
• Mereo Biopharma receives Nasdaq minimum bid price deficiency letter
• Mereo Biopharma stock rises as alvelestat high dose shows promise in lung disease in phase 2 trial
• Mereo BioPharma Group GAAP EPS of -£0.05, revenue of £36.46M
• Mereo Bio reports positive results from Phase 1b/2 alvelestat study in COVID-19 respiratory disease
• Catalyst watch for next week: FOMC drama, events for Lowe's and Delta Air Lines, Rivian earnings
• Mereo Bio gains 7% on promising etigilimab + nivolumab data in solid tumors
• FDA grants Orphan Drug status to Mereo's AATD treatment alvelestat
• Mereo BioPharma, Ultragenyx report secondary endpoint data in trial for bone disorder
• ZBRA, FGEN, GOOGL and TCOM among after hours movers
• Mereo Biopharma adds Pierre Jacquet to board of directors
• Sensei downgraded, PT cut on program discontinuation, Gilead's Yescarta data, and more in analyst action
• Idera Pharmaceuticals, Beyond Air leads healthcare gainers; Mereo BioPharma, Portage Biotech among major losers
• Esperion sinks after Stifel downgrade, Community Health adds another bull; in today’s healthcare analyst action
• Mereo BioPharma and Cancer Focus Fund ink partnership for ovarian cancer study
• TSLA, NVTA, CHPT and NNOX among premarket gainers
• Mereo BioPharma Group reports FY results
• Mereo BioPharma priced its ADSs offering